Issue No. 811 (dated 9/17/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ANTH #CBMG #FPRX #INCY #MDCO #NVAX #PCRX #SGMO #ZIOP
MTSL published Issue #753 “Plentiful Platforms†on April 25, 2012. Most of our platform recommendations have made significant progress since then, and our subscriber base has grown substantially as well.
March 6, 2014 Below is a pdf for MTSL Issue #774 of the Medical Technology Stock Letter.
Pacira had good news this morning and the stock is up modestly. The company announced results from the first IMPROVE study to complete its prospective Phase 4 clinical program. The IMPROVE studies compare the difference in opioid use, total hospital cost and length of stay (LOS) between patients receiving Exparel (bupivacaine liposome injectable suspension) as[…]
Issue No. 808 (dated 8/6/15) of the Medical Technology Stock Letter from BioInvest includes the Biotech Sector Analysis as well as updates from the following companies found in the MTSL Portfolio: #ALKS #ANTH #BMRN #INCY #ISIS #MDCO #NKTR #NVAX #PCRX #SGMO #ZIOP
May 15, 2014 Below is a pdf for Issue 779 of the Medical Technology Stock Letter.
Pacira posts Phase 3 nerve block study; completes EXPAREL pilot hernia study. Pacira has posted the design and is about to begin a Phase III nerve block study with EXPAREL in patients undergoing thoracic surgery. The trial will enroll 180 patients and data collection is due by August. Nerve block is the next major market for[…]
Pacira Update (3-2-2015)
April 3, 2014 Below is a pdf for MTSL Issue #776 of the Medical Technology Stock Letter.
On a positive note, Pacira pre-released some of their key Q4 financials. The company expects Q4:12 and FY12 revenues to come in above Wall Street consensus estimates, driven by higher net sales of Exparel. Q4 sales of the drug are targeted at $7.8 million, and total revenues are estimated at $10.5 million, compared to $4.2[…]
